Anti-angiogenic treatment of gastrointestinal malignancies

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The scientific rationale for blocking angiogenesis in cancer treatment has been established over three decades.
• Vascular endothelial growth factor (VEGF) pathways are crucial in physiologic and pathologic angiogenesis, particularly in tumor development.

Purpose of the Study:

• To review the preclinical basis and clinical studies of anti-angiogenic therapies targeting VEGF in gastrointestinal cancers.
• To highlight the development and investigation of novel anti-VEGF approaches.

Main Methods:

• Review of preclinical studies demonstrating the role of VEGF in tumor angiogenesis.
• Analysis of clinical trials involving anti-VEGF agents such as Bevacizumab, soluble chimeric receptors, monoclonal antibodies, and tyrosine kinase inhibitors.
• Focus on anti-VEGF therapy applications in colorectal cancer (CRC) and other gastrointestinal malignancies.

Main Results:

• Bevacizumab, an anti-VEGF antibody, has demonstrated prolonged survival when combined with chemotherapy in metastatic colorectal cancer (CRC).
• Other anti-VEGF strategies, including soluble receptors, antibodies, and tyrosine kinase inhibitors, show promise in preclinical and early clinical investigations.
• Anti-VEGF therapy is being explored in challenging gastrointestinal cancers like pancreatic cancer and hepatocellular carcinoma.

Conclusions:

• Anti-angiogenic strategies targeting VEGF represent a significant advancement in cancer treatment, moving from preclinical research to clinical application.
• Bevacizumab is the first approved anti-angiogenic therapy for human epithelial malignancy, specifically metastatic CRC.
• Ongoing research and clinical trials are expanding the application of anti-VEGF therapies to a range of gastrointestinal cancers, including resistant types.